Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Takumi Kaku"'
Autor:
Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Yuki Funauchi, Takashi Hirai, Masato Yuasa, Yu Matsukura, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake, Atsushi Okawa
Publikováno v:
JBMR Plus, Vol 7, Iss 7, Pp n/a-n/a (2023)
ABSTRACT Patients on bone‐modifying agents (BMAs) for bone metastases are at risk of atypical femoral fractures (AFFs), which can lead to a sudden deterioration in performance status. In this study, we sought to determine the prevalence of radiogra
Externí odkaz:
https://doaj.org/article/e57212bf61924c1f8a0e496d8e4c4ba9
Autor:
Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Takashi Hirai, Masato Yuasa, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake, Atsushi Okawa
Publikováno v:
Journal of Bone Oncology, Vol 23, Iss , Pp 100301- (2020)
Background: As the life expectancy of cancer-bearing patients has increased, more patients with bone metastasis are receiving long-term treatment with bone-modifying agents (BMAs; e.g., zoledronate and denosumab), which are a risk factor for developi
Externí odkaz:
https://doaj.org/article/03e9096eaeca46f1941c67e07b0b0878
Autor:
null Takumi Kaku, null Yoto Oh, null Shingo Sato, null Hirotaka Koyanagi, null Yuki Funauchi, null Takashi Hirai, null Masato Yuasa, null Yu Matsukura, null Toshitaka Yoshii, null Tsuyoshi Nakagawa, null Satoshi Miyake, null Atsushi Okawa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79c5b48d302dc12eca1930e54e37052f
https://doi.org/10.1002/jbm4.10749/v3/response1
https://doi.org/10.1002/jbm4.10749/v3/response1
Autor:
Hirotaka Koyanagi, Toshitaka Yoshii, Tsuyoshi Nakagawa, Takumi Kaku, Yoto Oh, Atsushi Okawa, Shingo Sato, Masato Yuasa, Satoshi Miyake, Takashi Hirai
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 23, Iss, Pp 100301-(2020)
Journal of Bone Oncology, Vol 23, Iss, Pp 100301-(2020)
Highlights • Oncologic use of bone-modifying agents (BMAs) has been dramatically increasing. • Long-term BMA use is a risk factor for atypical femoral fracture (AFF). • We reviewed 721 patients with bone metastasis in a Japanese university hosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8dbf7eca78689fdffb3b963292cc0d9
https://pubmed.ncbi.nlm.nih.gov/32642421
https://pubmed.ncbi.nlm.nih.gov/32642421